ETTX Projected Dividend Yield
COM/ENTASIS THERAPEUTICS HLDGS INC ( NASDAQ : ETTX )Entasis Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens. Co.'s main product candidate, sulbactam-durlobactam, is an intravenous (IV), combination of sulbactam, an IV ß-lactam antibiotic, and durlobactam, an intravenous ß-lactamase inhibitor, that Co. is developing for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. Co.'s second late-stage product candidate, zoliflodacin, is an orally administered molecule being developed for the treatment of uncomplicated gonorrhea. 20 YEAR PERFORMANCE RESULTS |
ETTX Dividend History Detail ETTX Dividend News ETTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |